SONA has announced it is now working on it’s Health Canada and FDA Submission. The company has secured more non-binding letters of intent for up to 4.7M which is over double their original estimate as well as begun to place some of it’s equipment and technology for manufacturing purposes. Check here for the original.
” The work will take place in MRIGlobal’s Kansas City laboratories and will assess $SONA’s test using live SARS-CoV-2 virus following its past, successful internal evaluation using gamma irradiated virus. The EUA studies will follow the FDA’s guidance for antigen testing, including assessments for sensitivity, specificity, cross-reactivity and interfering substances using patient samples and live viral culture samples. The results of this assessment will be included as part of the Company’s regulatory submissions to Health Canada and the FDA for EUA approval.”
As it stands although this news is not exactly what we had hoped for we are still very bullish on it as it is a good sign to see the Health Canada and FDA submission news. Check here to see a practical but pertinent timeline of our due diligence on the company.
Disclaimer: We own shares of SONA. This is not investment advice.
All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. Candlr is not receiving payment or commissions from companies for shared content on Candlr website unless its specified. View full disclaimer HERE.